Ejaculatory dysfunction: Why all α-blockers are not equal

BJU International

Volumn 92, Issue 9, 2003, Pages 876-877

  Andersson, K E ^a   Wyllie, M G ^b,c  

^a Department of Clinical Pharmacology ^*  (Sweden)

^b Urodoc Ltd   (United Kingdom)

^c Urodoc Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; TAMSULOSIN;

COMORBIDITY; DISEASE ASSOCIATION; EJACULATION DISORDER; HUMAN; HYPERTENSION; NOTE; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SEXUAL DYSFUNCTION; SIDE EFFECT; URODYNAMICS;

ADRENERGIC ALPHA-ANTAGONISTS; EJACULATION; HUMANS; MALE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 0346749696     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2003.04590.x     Document Type: Note

References (15)

1. McVary KT. Sexual dysfunction in men with lower urinary tract symptoms and benign hyperplasia: an emerging link. BJU Int 2003; 91: 770-1
2. Pool JL. Role of the sympathetic nervous system in hypertension and benign prostatic hyperplasia. Br J Clin Prac 1994; 74 (Suppl.): 13-7
3. Oishi K, Boyle P, Barry MJ et al. Epidemiology and natural history of benign prostatic hyperplasia. In Denis L, Griffiths K, Khoury S et al. eds. 4th International Consultation on BPH. Plymouth UK: Plymbridge Distributors Ltd, Health Publication Ltd, 1998: 23-59
4. Rosen R, O'Leary M, Altwein J et al. LUTS and male sexual dysfunction: the multinational survey of the ageing male [MSAM-7]. J Urol 2003; 161: Abstract 5000161
5. Jardin A, Andersson K-E, Chapple C et al. Alpha-adrenoceptor antagonists in the treatment of BPH. In Chatelian C, Denis L, Foo KT, Khoury S McConnell J eds Proceedings of the 5th International Consultation on Benign Prostatic Hyperplasia. Plymouth UK: Plymbridge Distributors Ltd, Health Publication Ltd, 2001
6. Andersson K-E, Lepor H, Wyllie MG. Prostatic alpha1-adrenoceptors and uroselectivity. Prostate 1997; 30: 202-5
7. Master VA, Turek PJ. Ejaculatory physiology and dysfunction. Urol Clin N Am 2001; 28: 363-75
8. Andersson K-E, Wagner G. Physiology of penile erection. Physiol Rev 1995; 75: 191-236
9. AUA practice Guidelines Committee. AUA Guideline on the management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and Treatment recommendations. J Urol 2003; 170: 530-47
10. Prescribing information: Flomax (tamsulosin hydrochloride) capsules. Physicians Desk Reference, 55th edn. Montvale NJ: Medical Economics Company, 2002: 974-7
11. Narayan P, Lepor H. Long-term open-label, phase III multi-center study of tamsulosin in benign prostatic hyperplasia. Urology 2001; 57: 466-70
12. Fourcroy JL. Center for Drug Evaluation and Research. Approval package for Flomax capsules, summary NDA 020579. Medical Reviewer 1997: 35-7
13. Giuliano F, Bernabe J, Droupy S et al. Comparison of the effects of tamsulosin and alfuzosin on neurally-evoked increase of bladder neck and seminal vesicle pressure in rats. BJU Int 2004; 93: in press
14. Pulito V, Li X, Varga SS et al. An investigation of the uroselective properties of four novel alpha (1a)-adrenergic receptor subtype-selective antagonists. J Pharmacol Exp Ther 2000; 294: 224-9
15. Taguchi K, Schafers RF, Michel MC. Radioreceptor assay analysis of tamsulosin and terazosin. Br J Clin Pharmacol 1998; 45: 49-55